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Abstract 
A critical appraisal of the current strategies for the synthesis of enantiopure drugs is presented, along with a system-
atic background for the computational design of stereoselective porous polymers. These materials aim to achieve the 
enantiomeric excess of any chiral drug, avoiding the racemic separation. Particular emphasis is given to link statistical 
mechanics methods to the description of each one of the experimental stages within the catalyst’s synthesis, setting a 
framework for the fundamental study of the emerging field of molecularly imprinted catalysts.
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Background
Nature as a whole is a chiral system, many of the mol-
ecules that constitute living organisms are chiral and, in 
the vast majority of cases, preference is shown for one 
of the enantiomers. For example, proteins are formed 
exclusively of the L form of amino acids. Meanwhile, sac-
charide units of the D form singularly constitute carbo-
hydrates; in the same manner, enantiomeric forms in the 
building blocks of DNA and RNA (d-ribose or d-deoxy-
ribose) have been observed [1].
Enantiomers have the same physical properties with 
the exception that they interact differently with polarised 
light. Regarding the chemical properties, both enantiom-
ers solely differ in their reactivity with other chiral mol-
ecules. Hence, a chiral molecule only manifests itself as 
such by the influence of polarised light or other chiral 
molecules.
Biological systems, such as proteins and enzymes that 
catalyse life’s essential reactions have a three-dimensional 
structure and establish preferences to interact with one 
of the enantiomers of other molecules. The effect of these 
interactions is the basis for the study of chiral drugs. As 
a result of their chirality, racemic drugs can have dif-
ferent effects on our bodies. There are chiral drugs in 
which each one of the enantiomers could produce oppo-
site effects in the organism, in other cases, the effect is 
similar, but one of the enantiomers is more active than 
the other (eutomer and distomer, respectively). While 
in some cases, one enantiomer is active and the other is 
inactive and also can occur that one enantiomer has a 
beneficial effect meanwhile the other is toxic.
Through an evolutionary pathway, nature has become 
stereoselective, being capable of synthesising the best for 
a purpose of the enantiomers. A practically endless list 
of chiral compounds provided by nature can be com-
piled. The tobacco leaves only produce the levorotatory 
S-nicotine. The coca only makes S-cocaine. The sugar-
cane generates d-sucrose exclusively. Limonene is an 
interesting case, which implies that genetic information 
drives the biosynthesis of the enantiomers, the dextroro-
tatory d-limonene is found in the orange or lemon peel. 
Meanwhile, in the mint, it is found as the levorotatory 
l-limonene and in the turpentine (derived from pines) as 
the racemic mixture (±)-limonene [2].
Chiral drugs dominate the modern pharmaceutical 
landscape, making up to 40–50% of the market in 2013 
with 9 of the top 10 bestseller drugs being chiral [3]. 
These drugs are sold as racemic mixtures or as a single 
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enantiomer. Currently, there is a significant trend in the 
pharmaceutical industry to produce what is called “chiral 
switches”: chiral drugs already commercialised as race-
mates that could be developed as a single enantiomer 
[4]. The idea behind these chiral switches is the fact that 
the enantiomers exhibit different behaviour when they 
are exposed to the chiral environment that is the human 
body. This discrimination between enantiomers—or chi-
ral recognition—depends on the degree of interaction 
that each enantiomer exhibits with the chiral binding site 
in the body.
Pointing out the enantioselective action of chiral drugs 
at the beginning of modern pharmacology was regarded 
as vain within the global profile of drug activity. Nowa-
days, this is no longer the case. At this very moment, 
most of the existing patents for drugs consisting of race-
mic mixtures are coming to an end and the race to obtain 
new ones for enantiopure production has already begun 
[5].
Therefore, there is a need for systematic studies to 
enhance the understanding of eutomers and to guide 
their stereoselective synthesis. This work introduces the 
most relevant molecular simulation methods to help in 
the design of enantiopure molecularly imprinted cata-
lysts, EMICs. A well-designed EMIC would create a con-
siderable impact in the way the synthesis of enantiopure 
drugs is performed. An EMIC could circumvent the effort 
involved in separating racemic mixtures and enable direct 
access to the eutomer, which in turn reduces the neces-
sary dosage and the chronic side effects of the racemate as 
well as simplifying dosage-effect studies.
The description of different molecular simulation tech-
niques for the study and development of these efficient 
catalysts throughout their synthesis stages is the princi-
pal purpose of this contribution and the central pillar of 
our on-going research efforts, translating the principles 
of enzyme catalysis to the design of EMICs from a molec-
ular perspective.
Currents paths from racemate to enantiopure drugs
The separation of racemates into their enantiomers is a 
difficult task, e.g. distillation cannot be employed, as both 
enantiomers will have the same bubble point. To achieve 
an enantiopure separation the technique used must dis-
criminate based on the stereo orientation of the enanti-
omer. The most relevant categories of chiral drugs and the 
current ways to obtain the enantiopure ones follow.
There are three categories that all chiral drugs fall 
under [6].
  • Most chiral drugs have one key bioactive enantiomer. 
In this case, one of the enantiomers, the eutomer, 
is much more active and efficient than the other. 
The distomer can either be less active, toxic or pro-
duce undesirable effects. Drugs that fall under this 
category will often benefit from the synthesis of an 
enantiopure drug, e.g. ethambutol, whereas the (S,S)-
(+)-enantiomer is used to treat tuberculosis, the 
(R,R)-(−)-ethambutol causes blindness [7].
  • Some chiral drugs have equally bioactive enan-
tiomers. Here, the two enantiomers would have 
the same activity and identical pharmacodynamic 
properties. There are only a few chiral medications 
that may fall under this category, but none has been 
confirmed [6].
  • Finally, some chiral drugs can undergo chiral inver-
sion in the body. These drugs have the unique prop-
erty that the eutomer or distomer can be converted 
into the other by our body. For these drugs, it can be 
unnecessary to develop a single enantiomer drug. For 
example, in the case of ibuprofen, while the racemic 
mixture is 50/50 when administered, some distomers 
are converted into eutomers in the body, ultimately 
making the drug more potent [8].
There are six main ways to obtain enantiopure drugs 
from either racemic mixtures or substrates [9].
  • Synthesis of diastereomeric salts by treatment with 
an enantiomer. The salts of the two enantiomers have 
different solubilities, allowing them to be separated 
from each other.
  • Utilising the various reaction rates of the two enan-
tiomers with the addition of a different enantiopure 
compound. Up to 50% of the enantiomer that reacts 
more slowly can be recovered from the racemate.
  • Other resolution of racemates also takes advantage 
of the differing reaction rates to separate the mixture. 
However, the unrecovered enantiomer is converted 
back into a racemic mixture. This process is then 
repeated until a higher yield of the eutomer is recov-
ered.
  • Some approaches take advantage of naturally occur-
ring enantiopure compounds. The natural enan-
tiopure compound is modified to create the desired 
enantiopure drug. This method is extremely useful 
when the product you want has a similar chemical 
structure to the naturally occurring enantiomer and is 
used in such cases.
  • Synthesis of the enantiopure compound from prochi-
ral substrates by the introduction of a chiral auxiliary 
to the racemic substrate mixture to separate the two 
enantiomers. The auxiliary is then removed post-sep-
aration. This method is effective, but the auxiliary is 
required in a stoichiometric quantity. Because of this, 
the auxiliary must be cheap and easy to produce.
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  • Selective adsorption, a stereoselective adsorbent is 
used to remove only one enantiomer thoroughly 
from the racemate. This method has a large advantage 
over using an auxiliary because sub-stoichiometric 
amounts of the adsorbent can be used (and re-used) 
for an adequate separation. Current separation tech-
niques include the use of enzymes and homogeneous 
chiral metal containing complexes.
Here, we propose EMICs as a seventh alternative to 
obtaining the eutomer avoiding the racemic separation. 
Such a catalyst could be done by exploiting on the field 
of molecularly imprinted polymers (MIPs) [10], the basic 
concepts of molecular imprinting can be adopted to cre-
ate a catalytic polymer network that will promote the 
transition state (TS) of a particular reaction in a lock and 
key fashion.
Following nature’s example
Natural enzymes possess an arrangement of functional 
groups responsible for their specificity [11, 12]. The 
substrate-enzyme binding interactions are rather com-
plex and consist of a combination of electrostatic inter-
actions, hydrogen bonds, hydrophobic interactions, 
and other contributions. Then, some prerequisites have 
to be fulfilled for the preparation of a material showing 
enzyme-like catalytic activity towards the eutomer, i.e. to 
construct an EMIC.
First, a cavity has to be made with a defined shape. This 
shape can correspond to the substrate or, even better, to 
the TS of the reaction. Due to the TS instability a transi-
tion state analogue, TSA, must be found. The cavity can 
also adopt the shape of the eutomer. Functional groups 
have to be introduced to act as binding sites within the 
cavity in a defined stereochemistry. These requirements 
were introduced with the imprinting protocol conceptu-
alised by Dickey [13] and implemented by Wulff [14] and 
Mosbach [15].
The schematic and components of the imprinting pro-
tocol via TS can be seen in Fig.  1a, b. The polymeris-
able functional groups are usually bound by covalent 
or non-covalent interaction to the TS. This complex is 
then copolymerized in the presence of large amounts of 
cross-linking agent and inert solvent (the latter acting as a 
porogen). After removal of the TS, an imprint containing 
functional groups in a certain orientation remains in the 
highly cross-linked polymer. The shape of the imprint and 
the arrangement of the functional groups are complemen-
tary to the structure of the TS. This procedure furnishes 
porous polymers with a permanent pore structure and a 
high inner surface area, where the preferred binding for 
the TS lowers the activation energy of the desired reaction 
and has thus a catalytic effect on the reaction rate. This 
concept was already postulated by Pauling [16] and later 
discussed more in detail by Jencks [17]. The concept was 
shown to be correct by Lerner [18] and by Schultz [19], 
independently, by generating antibodies against a stable 
TSA of a reaction.
Following the technique described above, recent years 
have seen remarkable progress in the design of molecu-
larly imprinted catalysts [20]. Numerous reviews on the 
molecular imprinting procedure have been published 
[21–27]. However, a comparison between these catalysts 
and enzymes [22], shows that enzymes are still in every 
case several orders of magnitude catalytically more effi-
cient, but in a few cases, the efforts have reached the 
activity of catalytic antibodies, e.g., in the hydrolysis of 
carbamates [28].
What do modelling techniques have to offer for the design 
of better MICs and EMICs?
The binding site homogeneity in enzymes is high, 
whereas MICs, have a broad distribution of activity, and 
there is no method available at the moment to reduce 
this broadness significantly. Though some progress has 
been made in the preparation of MICs, for modest use 
in industry and wider application in research, refining 
the experimental imprinting procedures with insights 
gained from statistical mechanics tools could make fur-
ther developments.
Improvement of the mass transfer in the imprinted 
networks, reduction of the polyclonality of cavities, an 
increase of available active sites (in particular with the 
frequent noncovalent interaction) and development of 
further suitable groupings for catalysis are just some 
problems at the forefront of investigations [20, 22]. Some 
researchers have concluded that a larger extent of self-
assembly can result in a higher specificity. Others have 
claimed that the shape of the imprinted cavity is the 
main aspect of molecular recognition and that a change 
in the form will result in a lower level of identification. 
More recently, more and more researchers tend to sup-
port a modest extent of self-assembly as the condition 
for the strongest molecular recognition. Undoubtedly, 
the design of MICs is attracting an extensive research 
effort [20].
The idea behind EMICs is clear and straightforward, 
but the huge pool of variables in its synthesis and char-
acterization requires some rational screening strategies. 
We believe these strategies could evolve from simultane-
ous and synergic use of modelling tools with experimen-
tal work for the sound design of EMICs in silico. All the 
variables involved in the synthesis can be independently 
controlled, and their impact systematically assessed to 
prepare better catalysts. With molecular models, we seek 
to understand how imprinted materials are created and 
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what happens to TSAs and substrate molecules in these 
imprinted cavities to become eutomers. This will help to 
elucidate the different contributions of each parameter to 
the overall catalytic effect with the use of proper control 
systems, for the ultimate developments of better MICs 
for various reactions and EMICs for specific diseases. 
Figure  1c, obtained through our molecular dynamics 
(MD) methodology [29], shows the complexation, polym-
erization and cavity rebinding points for a pyridine-selec-
tive polymer.
Some detailed atomistic simulations have been 
employed for the computational design of imprinted pol-
ymers [30–34]. Recently, a more general approach derives 
a set of design principles and backs up the possibility 
of efficiently imprinting drugs [35], although very few 
specific examples of molecular modelling efforts could 
be found for MICs design [20]. While some interesting 
insights have been gained [30–34], most of these efforts 
suffer from two significant drawbacks. First, they focus 
on a single cavity (neglecting issues related to the het-
erogeneity of binding sites and porosity). Second, the 
material optimisation is reduced to a simplified scoring 
function based on the internal energy of complexation, 
rather than on proper adsorption or rebinding isotherms 
or reaction yield as measured in experiments.
We should aim to develop models and methodologies 
that feature a sufficient level of realism and detail, specifi-
cally based on accurate force fields, and that reflect some 
underlying principles behind the materials formation 
and function. These protocols should imitate the actual 
process of MICs formation, characterization and applica-
tions within four stages of development:
Stage 1 involves a mixture of TSA (or substrate or prod-
uct), functional monomers and cross-linkers. Ab initio 
Fig. 1 a Main EMIC components. b Synthesis stages. c Computer graphics visualizations of three stages for a pyridine selective polymer: left final 
configuration of the equilibrium mixture of the functional monomer methacrylic acid (red), cross-linker ethylene glycol dimethacrylate (white), sol-
vent chloroform (green) and template pyridine (orange); centre same configuration with the solvent and template removed; right pyridine molecules 
rebinding sites. Model details can be found elsewhere [29]
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calculations are envisaged to identify the plausible TSA 
of the desired reaction, obtain the partial charge distribu-
tions of these structures, and describe the complex TSA 
cavity-regarding binding site energy. The equilibrium 
properties of the mixture (TSA, functional monomer, 
cross-linker and solvent) could be obtained by molecular 
dynamics [29] or Monte Carlo [35] approaches to mimic 
the synthesis conditions in NPT and NVT ensembles.
In Stage 2, the polymerization of functional monomers 
and cross-linkers should be modelled from the equili-
brated mixture structure (a direct outcome of Stage 1). 
The idea is to focus on the generation of the functional/
selective catalytic cavity-ignoring, for a while, the details 
of the network formation. However, the explicit account 
of the new bonds formed during the polymerization step 
can be attained by kinetic Monte Carlo [36].
In Stage 3, the imprint TSA is removed. The model can 
be further extended to imitate some post-formational 
modifications, such as cavity shrinking and introduc-
tion of defects. This resulting structure would serve as 
a porous matrix for both the structural characteriza-
tion and applications. The resulting model EMIC could 
be used as the material structure for adsorption studies. 
The grand canonical Monte Carlo (GCMC) method [37] 
is appropriate to describe the re-binding behaviour of the 
EMIC under study.
In Stage 4, before the reaction, the TSA is bound to 
the EMIC in a pre-equilibrium step. The bound TSA is 
converted under catalysis of the TSA-EMIC to the prod-
uct and is then released. At this final stage, the different 
reaction kinetics (regarding rates of reactions of differ-
ent orders of magnitude expected for the diffusion and 
binding of the template to the polymer) can be investi-
gated by using the probability-weighted dynamic Monte 
Carlo method [38]. Complex molecular geometries may 
require the employment of advanced techniques such as 
configurational bias Monte Carlo [39] and cavity/energy 
bias Monte Carlo [40] to efficiently explore the binding 
sites.
As briefly described above, required modelling tools for 
EMIC’s rational design protocol (models and methods) 
are available, but so far these tools remain unrelated to 
the field. The compilation of such a computational tool-
box would encompass linking various pieces of research 
together in a consistent workflow, standardising inputs 
and outputs between the stages and methods. Many 
aspects of the sketched protocol are challenging and 
require substantial expertise in the areas of molecu-
lar modelling, programming and statistical mechanics. 
However, the expected outcomes in the understanding of 
these systems are worth the effort.
The largest gain of the proposed theoretical approach 
to these systems is that it will allow going beyond current 
knowledge and exploring these novel formulations. How-
ever, the validation of any computer simulation strategy 
requires the comparison with nature; i.e. the model must 
be able to reproduce the essential properties of a system 
that has been already explored experimentally. An excel-
lent source for test cases is the first book in the area of 
MICs with its substantial amount of experimental work 
and applications [20].
Concluding remarks
This toolbox could be very useful in improving the scope 
and applicability of MICs for more advanced catalysis, 
as the EMICs proposed here, (i.e. the selective cataly-
sis of enantiopure drugs). The fundamental efforts of 
the described tasks would help to ask, and hopefully to 
answer, the “what if ” questions for a range of possible 
catalytic systems, focusing on the in silico performance 
rank of the candidate materials, bypassing the economic 
constraints of such search through real experiments. As 
a result, EMICs could be synthesised to corroborate, or 
dispute, the predictions and guide the ultimately neces-
sary experimental work.
For instance, one can compare the re-binding affinity of 
a synthesised EMIC using the TSA, against the theoreti-
cal adsorption affinity of that EMIC but imprinted with 
the TS. Such a comparison would serve as a characteri-
zation approach and pre-screening of plausible EMIC 
formulations. This type of study will be experimentally 
inconclusive, due to the instability associated with the 
TS. However, this useful exercise will be setting a theo-
retical limit to help identify the best TSA for a specified 
system. The presented computational techniques allow 
us to fulfil both characterization processes (i.e. the struc-
tural and the energetic ones) using an entirely controlled 
framework.
MICs are easy to prepare and handle, and the EMICs 
will inherit these qualities. MICs can be prepared in 
large quantities by suspension polymerization, and sta-
ble particles of uniform diameter can be easily obtained 
[20]. In addition to beads or broken particles, MICs can 
also be prepared in other very different forms, such as 
monoliths, microcapsules, membranes or surfaces [10]. 
MICs have both excellent mechanical and thermal sta-
bility. Frequently, they can be used for a long time in a 
continuous process, or they can be reused many times. 
As a result of their insolubility, they can be easily filtered 
off after a reaction, or they can be placed in a flow reac-
tor. Whereas enzymes and antibodies degrade under 
harsh conditions such as high temperature, chemically 
aggressive media, and high and low pH, MICs show bet-
ter behaviour in most cases, and they can be applied 
directly in chemical processes since they are rather sta-
ble materials.
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